Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT

Br J Haematol. 2018 Aug;182(3):418-422. doi: 10.1111/bjh.15407. Epub 2018 May 29.

Abstract

Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.

Keywords: JAK inhibitors; allogeneic stem cell transplant; fibrosis; mylelofibrosis; relapse.

MeSH terms

  • Adult
  • Disease Management
  • Drug Therapy
  • Female
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Lymphocyte Transfusion
  • Male
  • Middle Aged
  • Primary Myelofibrosis / mortality
  • Primary Myelofibrosis / therapy*
  • Recurrence
  • Retrospective Studies
  • Survival Analysis
  • Transplantation, Homologous
  • Treatment Outcome